Newer Pharmaceutical Agents for STEMI Interventions

Chakrabarti A. K., Patel S. J., Salazar R. L., Gopalakrishnan L., Kumar V., Rastogi U., ...Daha Fazla

Interventional Cardiology Clinics, cilt.1, sa.4, ss.429-440, 2012 (Scopus) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 1 Sayı: 4
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/j.iccl.2012.06.005
  • Dergi Adı: Interventional Cardiology Clinics
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.429-440
  • Anahtar Kelimeler: Fibrinolytics, STEMI, Thienopyridines, Thrombin inhibitors
  • İstanbul Üniversitesi Adresli: Evet

Özet

ST-elevation myocardial infarction (STEMI) causes 12.6% of deaths worldwide. Treatment strategies involve early revascularization by percutaneous coronary intervention and/or fibrinolytics, with adjunctive pharmacologic therapy. While antiplatelet therapy remains the cornerstone of pharmacologic management, newer antithrombotic therapies are showing benefit in the reduction of long-term thrombotic events following acute vessel occlusion. Future directions in adjunctive STEMI management include the use of hematopoietic stem cell therapy or growth factors to induce proliferation and differentiation of cardiac myocytes. © 2012 Elsevier Inc.